NGM Biopharmaceuticals Inc NGM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EDT
16.24UNCH (UNCH)
Volume
3,586
Close
16.24quote price arrow down-0.08 (-0.49%)
Volume
316,746
52 week range
10.49 - 27.25
Loading...
  • Open15.63
  • Day High16.54
  • Day Low15.54
  • Prev Close16.32
  • 52 Week High27.25
  • 52 Week High Date09/13/21
  • 52 Week Low10.49
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap1.305B
  • Shares Out80.37M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.69
  • YTD % Change-8.13

KEY STATS

  • Open15.63
  • Day High16.54
  • Day Low15.54
  • Prev Close16.32
  • 52 Week High27.25
  • 52 Week High Date09/13/21
  • 52 Week Low10.49
  • 52 Week Low Date05/11/22
  • Market Cap1.305B
  • Shares Out80.37M
  • 10 Day Average Volume0.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.69
  • YTD % Change-8.13

RATIOS/PROFITABILITY

  • EPS (TTM)-1.73
  • P/E (TTM)-9.39
  • Fwd P/E (NTM)-7.13
  • EBITDA (TTM)-130.055M
  • ROE (TTM)-40.61%
  • Revenue (TTM)68.78M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-196.39%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/02/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NGM Biopharmaceuticals Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to...
William Rieflin J.D.
Chairman of the Board
David Woodhouse Ph.D.
Chief Executive Officer, Director
Siobhan Mangini
President, Chief Financial Officer
Address
333 Oyster Point Blvd
South San Francisco, CA
94080-1978
United States

Top Peers

SYMBOLLASTCHG%CHG
MORF
Morphic Holding Inc
31.01-0.68-2.15%
MRUS
Merus NV
26.50-1.67-5.93%
IMGN
ImmunoGen Inc
5.27-0.12-2.23%
EDIT
Editas Medicine Inc
17.99-1.14-5.96%
MNKD
MannKind Corp
4.09-0.26-5.98%